EvoLution of Neoadjuvant TreatMent in 'Triple-negative' or 'HER-2-positive' Breast Cancer Diagnosed in the EaRly Phase

The primary objective of this study is to describe the percentage of patients with HER2-positive and Triple Negative tumour underwent neoadjuvant treatment in clinical practice during the past 5 years out of total number of patients who underwent neoadjuvant treatment, regardless molecular subtypes. Secondary objectives The secondary objectives which are limited to molecular subtypes of study interest, HER2-positive and Triple Negative tumours, are follow reported:

• To perform a descriptive analysis on neoadjuvant treatment choice according to molecular subtype and initial staging;

• To perform a descriptive analysis on clinical and tumour pathological characteristics according to molecular subtypes and initial staging;

• To perform radiological response descriptive analysis achieved with neoadjuvant therapy according to treatment and instrumental examination type (for example: breast MRI, breast ultrasound or mammography);

• To perform a descriptive analysis of surgical procedures for both, the breast and the axilla, according to radiological tumour response, initial staging and molecular subtypes;

• To perform a descriptive analysis on therapies performed in adjuvant setting according to neoadjuvant treatment type, initial staging and molecular subtypes;

• To describe and to analyse the eligibility criteria evolution in neoadjuvant treatment setting during the last 5 years;

• To perform a descriptive analysis on pathological complete response (cPR) according to neoadjuvant treatment, molecular subtypes and initial staging;

• To evaluate disease-free survival (DFS) according to pCR and molecular subtypes;

• To evaluate overall survival (OS) according to pCR and molecular subtypes.